Assessment of protein function following cross-linking by α-dicarbonyls

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 195-200

  Miller, Antonia G ^a   Gerrard, Juliet A ^a  

^a UNIVERSITY OF CANTERBURY   (New Zealand)

Author keywords

3,5 dimethylpyrazole 1 carboxamidine; Aminoguanidine; Protein cross linking; Ribonuclease A; dicarbonyl

Indexed keywords

1,2 DICARBONYL DERIVATIVE; 2,3 BUTANEDIONE; 3,5 DIMETHYLPYRAZOLE 1 CARBOXAMIDINE; AMIDINE; AMINOGUANIDINE; GLYOXAL; METHYLGLYOXAL; RIBONUCLEASE A; UNCLASSIFIED DRUG;

AGING; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME INHIBITION; GLYCATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CROSS LINKING; PROTEIN FUNCTION; REACTION ANALYSIS;

EID: 23744455047     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.024     Document Type: Conference Paper

References (15)

1. VASAN, S. et al. 1996. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382: 275-278.
2. WOLFFENBUTTEL, B.H.R. et al. 1998. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. USA 95: 4630-4634.
3. ASIF, M. et al. 2000. An advanced glycation endproduct crosslink breaker can reverse age-related increases in myocardial stiffness. Proc. Natl. Acad. Sci. USA 97: 2809-2813.
4. THORNALLEY, P.J. & H. MINHAS. 1999. Rapid hydrolysis and slow α, β-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochem. Pharmacol. 57: 303-307.
5. OTURAI, P.S. et al. 2000. Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats. Metab. Clin. Exp. 49: 996-1000.
6. BROWNLEE, M., et al. 1986. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632.
7. THORNALLEY, P.J., A. YUREK-GEORGE & O.K. ARGIROV. 2000. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem. Pharmacol. 60: 55-65.
8. PRICE, D.L. et al. 2001. Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 276: 48967-48972.
9. VOZIYAN, P.A. et al. 2003. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J. Biol. Chem. 278: 46616-46624.
10. CULBERTSON, S.M. et al. 2003. Paradoxical impact of antioxidants on post-Amadori glycoxidation: counterintuitive increase in the yields of pentosidine and N-carboxymethyllysine using a novel multifunctional pyridoxamine derivative. J. Biol. Chem. 278: 38384-38394.
11. MILLER, A.G., S.J. MEADE & J.A. GERRARD. 2003. New insights into protein crosslinking via the Maillard reaction: structural requirements, the effect on enzyme function, and predicted efficacy of crosslinking inhibitors as anti-aging therapeutics. Bioorg. Med. Chem. 11: 843-852.
12. Fu, M.X. et al. 1994. Glycation, glycoxidation, and crosslinking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43: 676-683.
13. HAYASE, F., Y.H. KIM & H. KATO. 1991. Inhibition of the protein crosslinking in a Maillard reaction by aminoguanidine and semicarbazide. Agric. Biol. Chem. 55: 1435-1436.
14. WATKINS, N.G., S.R. THORPE & J.W. BAYNES. 1985. Glycation of amino groups in protein. Studies on the specificity of modification of RNase by glucose. J. Biol. Chem. 260: 10629-10636.
15. BROCK, J.W.C. et al. 2003. Proteomic analysis of the site specificity of glycation and carboxymethylation of ribonuclease. J. Proteome Res. 2: 506-513.